The Wegovy label lists acute pancreatitis in the Warnings and Precautions section. The reported incidence in clinical studies is low, but not zero.

The risk doesn't depend on diabetic status. Pancreatitis has been reported across both diabetic and non-diabetic populations on these peptides.

The classic presentation is severe persistent abdominal pain, often radiating to the back, sometimes with nausea and vomiting.

That isn't the routine GI side-effect pattern. It's the symptom that pulls the peptide out of "feels normal" and into "needs evaluation."